한글목차

세계 림프종 치료 시장 규모는 2023년 133억 달러에 달했습니다. 향후 IMARC Group은 2024-2032년 연평균 성장률(CAGR)이 7.5%로 2032년까지 시장 규모가 260억 달러에 달할 것으로 예상하고 있습니다.

림프종은 림프계에 비정상적인 악성 세포가 급속히 발생하는 것을 특징으로 하는 암의 일종입니다. 일반적으로 림프절, 비장, 흉선 및 골수에 있는 백혈구(WBC), 즉 림프구를 표적으로 삼아 신체의 면역 반응을 방해합니다. 그 결과 환자는 림프절 부종, 고열, 체중 감소, 호흡곤란, 피로감을 경험하게 됩니다. 일반적으로 사용되는 림프종 치료에는 방사선 치료, 화학요법, 단클론항체 치료, 적극적 감시요법, 골수 이식, 면역치료제 등이 있습니다. 이러한 치료법은 호지킨 림프종과 비호지킨 림프종 모두 치료에 널리 사용됩니다.

전 세계적으로 비호지킨림프종의 유병률이 증가하고 있는 것은 시장 성장을 촉진하는 중요한 요인 중 하나입니다. 또한, 이러한 질병에 걸리기 쉬운 노인 인구의 증가도 시장 성장을 촉진하고 있습니다. 이와 함께 림프종에 대한 대중의 인식이 높아지면서 림프종 진단 기술 및 치료법에 대한 대중의 인식이 높아진 것도 시장 전망을 밝게 하고 있습니다. 병원 및 기타 진단 센터는 컴퓨터 단층촬영(CT), 자기공명영상(MRI), 양전자방사선단층촬영(PET) 스캔과 같은 혁신적인 검사 및 영상 기술을 사용하여 암세포를 정확하게 식별하고 적시에 치료할 수 있도록 돕고 있습니다. 또한, 단백질 간 결합을 억제하고 암세포에 대한 T세포의 반응성을 향상시키는 혁신적인 면역 체크포인트 억제제 개발 등 다양한 기술 발전이 시장 성장에 기여하고 있습니다. 이 외에도 종양학 부문의 광범위한 연구개발(R&D) 활동, 의료 인프라의 전반적인 개선 등이 시장을 더욱 견인할 것으로 예상됩니다.

본 보고서에서 다루는 주요 질문들

• 세계 림프종 치료 시장은 지금까지 어떻게 성장해왔고, 앞으로 어떻게 발전할 것인가?
• COVID-19는 세계 림프종 치료 시장에 어떤 영향을 미쳤을까?
• 주요 지역 시장이란?
• 유형별 시장 분석은?
• 검사 유형별 시장 분석은?
• 약제별 시장 현황은?
• 산업 가치사슬의 다양한 단계는 무엇인가?
• 업계의 주요 촉진요인과 과제는 무엇인가?
• 세계 림프종 치료 시장의 구조와 주요 진출 기업은?
• 업계의 경쟁은 어느 정도인가?

목차

제1장 서문

제2장 조사 범위와 조사 방법

• 조사 목적
• 이해관계자
• 데이터 소스
  • 1차 정보
  • 2차 정보
• 시장 추정
  • 상향식 접근
  • 하향식 접근
• 조사 방법

제3장 주요 요약

제4장 소개

• 개요
• 주요 업계 동향

제5장 세계의 림프종 치료 시장

• 시장 개요
• 시장 실적
• COVID-19의 영향
• 시장 예측

제6장 시장 내역 : 유형별

• 호지킨림프종
• 비호지킨림프종

제7장 시장 내역 : 검사 유형별

• 화학요법
• 방사선 치료
• 면역요법
• 표적요법
• 생물학적 요법
• 기타

제8장 시장 내역 : 약제별

• Adcetris
• Rituxan
• Opdivo
• Imbruvica
• Keytruda
• Revlimid
• 기타

제9장 시장 내역 : 지역별

• 북미
  • 미국
  • 캐나다
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 인도네시아
  • 기타
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 러시아
  • 기타
• 라틴아메리카
  • 브라질
  • 멕시코
  • 기타
• 중동 및 아프리카
  • 시장 동향
  • 시장 내역 : 국가별
  • 시장 예측

제10장 SWOT 분석

• 개요
• 강점
• 약점
• 기회
• 위협

제11장 밸류체인 분석

제12장 Porter's Five Forces 분석

• 개요
• 구매자의 교섭력
• 공급 기업의 교섭력
• 경쟁 정도
• 신규 참여업체의 위협
• 대체품의 위협

제13장 가격 분석

제14장 경쟁 상황

• 시장 구조
• 주요 기업
• 주요 기업 개요
  • Abbott Laboratories
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc.
  • Novartis International AG
  • Spectrum Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Ltd.
  • Teva Pharmaceutical Industries Ltd.

영문목차

The global lymphoma treatment market size reached US$ 13.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 26.0 Billion by 2032, exhibiting a growth rate (CAGR) of 7.5% during 2024-2032.

Lymphoma refers to a type of cancer characterized by the rapid development of abnormal malignant cells in the lymphatic system. It usually targets the white blood cells (WBCs), or lymphocytes, in lymph nodes, spleen, thymus and bone marrow and impairs the immune response of the body. As a result, the patient develops swelling in the lymph nodes, high fever, weight loss, dyspnea and fatigue. Some of the commonly used lymphoma therapeutics include radiation, chemo and monoclonal antibody therapy, active surveillance, bone marrow transplant and immunotherapy drugs. These therapeutics are widely used for the treatment of both Hodgkin and non-Hodgkin lymphoma.

The increasing prevalence of non-Hodgkin lymphoma across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, the increasing awareness among the masses regarding the available diagnostic technologies and treatment alternatives for lymphoma is also creating a positive outlook for the market. Hospitals and other diagnostic centers are using innovative tests and imaging technologies, such as computed tomography (CT), Magnetic Resonance Imaging (MRI) and positron emission tomography (PET) scans, for accurate identification of the cancer cells and timely treatment. Additionally, various technological advancements, including the development of innovative immune checkpoint inhibitors, which block proteins from binding together and increase the response strength of T-cells against cancer cells, are contributing to the market growth. Other factors, including extensive research and development (R&D) activities in the field of oncology, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global lymphoma treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, test type and drug.

Breakup by Type:

Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Breakup by Test Type:

Chemotherapy

Radiation Therapy

Immunotherapy

Targeted Therapy

Biologic Therapy

Others

Breakup by Drug:

Adcetris

Rituxan

Opdivo

Imbruvica

Keytruda

Revlimid

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

• How has the global lymphoma treatment market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global lymphoma treatment market?
• What are the key regional markets?
• What is the breakup of the market based on the type?
• What is the breakup of the market based on the test type?
• What is the breakup of the market based on the drug?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global lymphoma treatment market and who are the key players?
• What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Lymphoma Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Hodgkin Lymphoma
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Non-Hodgkin Lymphoma
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Test Type

• 7.1 Chemotherapy
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Radiation Therapy
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Immunotherapy
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Targeted Therapy
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Biologic Therapy
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Others
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by Drug

• 8.1 Adcetris
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Rituxan
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Opdivo
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Imbruvica
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Keytruda
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Revlimid
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast
• 8.7 Others
  • 8.7.1 Market Trends
  • 8.7.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Bristol-Myers Squibb Company
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Eli Lilly and Company
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 F. Hoffmann-La Roche Ltd.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 SWOT Analysis
  • 14.3.5 Johnson & Johnson Services, Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Merck & Co. Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Novartis International AG
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Spectrum Pharmaceuticals, Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Takeda Pharmaceutical Company Ltd.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Teva Pharmaceutical Industries Ltd.
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis